Insider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells $5,730,300.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $573.03, for a total value of $5,730,300.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,816,514.28. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total transaction of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $568.83, for a total transaction of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total transaction of $209,609.40.
• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56.
• On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.86, for a total value of $5,778,600.00.
• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total transaction of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total transaction of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total value of $5,778,900.00.

United Therapeutics Trading Down 0.6%

Shares of NASDAQ:UTHR opened at $575.79 on Friday. The stock’s fifty day simple moving average is $556.50 and its two-hundred day simple moving average is $506.65. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The stock has a market cap of $24.44 billion, a PE ratio of 21.25, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.63 EPS. On average, sell-side analysts forecast that United Therapeutics Corporation will post 27.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on UTHR. Bank of America raised their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. UBS Group raised their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Royal Bank Of Canada decreased their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. Wellington Management Group LLP increased its holdings in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the period. Darwin Global Management Ltd. purchased a new stake in United Therapeutics during the 3rd quarter valued at about $317,617,000. Norges Bank bought a new position in United Therapeutics during the 4th quarter worth approximately $293,418,000. Avoro Capital Advisors LLC grew its position in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.